You can buy or sell AMAG and other stocks, options, ETFs, and crypto commission-free!
AMAG Pharmaceuticals, Inc. Common Stock, also called AMAG Pharmaceuticals, is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Read More The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
AMAG Pharmaceuticals Inc.
Shares of AMAG Pharmaceuticals Inc. fell 6% after the company announced that its Phase 3 trial of Makena, a progestin therapy to reduce the risk of preterm birth, did not meet its primary endpoints. The trial, which enrolled 1700 patients, did not show a statistically significant difference between the treatment and placebo arms in preterm deliveries at less than 35 weeks. The trial also did not show a difference in neonatal morbidity and mortality, the company said. Makena is currently approved as a therap...
March of Dimes and AMAG Pharmaceuticals, Inc., Announce First Joint Supportive Pregnancy Care Program
First Site Launches in Springfield, Mass. Offering an Innovative Model of Group Prenatal Care ARLINGTON, Va. and WALTHAM, Mass., March 20, 2019 (GLOBE NEWSWIRE) -- March of Dimes and AMAG Pharmaceuticals, Inc. (AMAG) today announced Baystate Medical Center’s Wesson Women’s Clinic in Springfield, Mass. as the first Supportive Pregnancy Care (SPC) site, supported by AMAG to help improve mom and baby health during pregnancy, labor and delivery, and infancy. The March of Dimes SPC program offers prenatal ca...
Simply Wall StMar 14
Volatility 101: Should AMAG Pharmaceuticals (NASDAQ:AMAG) Shares Have Dropped 41%?
Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more than offset the losers So we wouldn’t blame long term AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shareholders for doubting their decision to hold, with the stock down 41% over a half decade. And it’s not just long term holders hurting, because the stock is down 35% in the last year. Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days. This could be...
Expected May 2, Pre-Market